Identifying and Characterizing Preclinical MS
Part of paid clinical trials in North Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT05787795
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- biological samples — OTHERblood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
Study Details
The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.
Key Dates
- Start date
- Jun 21, 2022
- Status verified
- Nov 2025
- Primary completion
- Jun 30, 2032
- Completion
- Jun 30, 2033
Study Design
- Enrollment
- 1,000 participants (estimated)
Primary Outcome Measure
To build a machine learning model of risk prediction [ Time Frame: ongoing prospective study ]
Central Contacts
- Erin Longbrake, MD860-287-6100
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale University | North Haven | Connecticut | 06473 | Erin Longbrake, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in North Haven, CT
By condition
By specialty
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPHASE1 · Recruiting · Hoffmann-La Roche · Stanford, California
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama